Evaluation of a self-nanoemulsifying docetaxel delivery system

  • Biomed Pharmacother. 2019 Jan;109:2427-2433. doi: 10.1016/j.biopha.2018.11.110.
S Akhtartavan  1 ,  M Karimi  1 ,  K Karimian  2 ,  N Azarpira  3 ,  M Khatami  4 ,  H Heli  5
Affiliations
  • 1. Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • 2. Arasto Pharmaceutical Chemicals Inc., Yousefabad, Jahanarar Avenue, Tehran, Iran.
  • 3. Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • 4. Nanobioeletrochemistry Research Center, Bam University of Medical Sciences, Bam, Iran.
  • 5. Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: [email protected].
PMID: 30551502 DOI: 10.1016/j.biopha.2018.11.110
Abstract

A self-nanoemulsifying drug delivery system (SNEDDS) was developed as a novel route to enhance the efficacy of docetaxel lipophilic drug. SNEDDS comprised ethyl oleate, Tween 80 and poly(ethylene glycol) 600, as oil, surfactant and co-surfactant, and formed stabilized monodispersed oil nanodroplets upon dilution in water. SNEDDS represented encapsulation efficiency and loading capacity of 21.4 and 52.7%, respectively. The docetaxel release profile from the drug-loaded SNEDDS was recorded, its effectiveness against MCF-7 cell line was investigated, and an IC50 value of 0.98 ± 0.05 μg mL-1 was attained. The drug-loaded SNEDDS was administrated in rats, and the pharmacokinetic parameters of maximum concentration of 22.2 ± 0.8 μg mL-1, time to attain this maximum concentration of 230 min, and area under the curve of 1.71 ± 0.18 μg min mL-1 were obtained. The developed SNEDDS formulation can be represented as an alternative to docetaxel administration.

Keywords
Anticancer drug; Breast cancer; MCF7 cell; Nanoemulsion; Taxotere.
Products